These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 16879583)

  • 1. Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma.
    Silva Paula J; Jorge R; Alves Costa R; Rodrigues Mde L; Scott IU
    Acta Ophthalmol Scand; 2006 Aug; 84(4):556-7. PubMed ID: 16879583
    [No Abstract]   [Full Text] [Related]  

  • 2. Intravitreal and intracameral bevacizumab to treat neovascular complications of retinopathy of prematurity.
    dell'Omo R; Kulkarni A; Franks WA
    Acta Ophthalmol; 2008 Sep; 86(6):698-700. PubMed ID: 18081905
    [No Abstract]   [Full Text] [Related]  

  • 3. Regression of neovascular iris vessels by intravitreal injection of bevacizumab.
    Mason JO; Albert MA; Mays A; Vail R
    Retina; 2006 Sep; 26(7):839-41. PubMed ID: 16963866
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical factors related to recurrence of anterior segment neovascularization after treatment including intravitreal bevacizumab.
    Saito Y; Higashide T; Takeda H; Murotani E; Ohkubo S; Sugiyama K
    Am J Ophthalmol; 2010 Jun; 149(6):964-972.e1. PubMed ID: 20381786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal bevacizumab in a patient with neovascular glaucoma.
    Kahook MY; Schuman JS; Noecker RJ
    Ophthalmic Surg Lasers Imaging; 2006; 37(2):144-6. PubMed ID: 16583637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes of patients with anterior segment neovascularization treated with or without intraocular bevacizumab.
    Lupinacci AP; Calzada JI; Rafieetery M; Charles S; Netland PA
    Adv Ther; 2009 Feb; 26(2):208-16. PubMed ID: 19234680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma.
    Yazdani S; Hendi K; Pakravan M
    J Glaucoma; 2007 Aug; 16(5):437-9. PubMed ID: 17700285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.
    Wakabayashi T; Oshima Y; Sakaguchi H; Ikuno Y; Miki A; Gomi F; Otori Y; Kamei M; Kusaka S; Tano Y
    Ophthalmology; 2008 Sep; 115(9):1571-80, 1580.e1-3. PubMed ID: 18440643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intravitreal bevacizumab for treatment of neovascular glaucoma. Report of 20 cases].
    Douat J; Auriol S; Mahieu-Durringer L; Ancèle E; Pagot-Mathis V; Mathis A
    J Fr Ophtalmol; 2009 Nov; 32(9):652-63. PubMed ID: 19892433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy.
    Jiang Y; Liang X; Li X; Tao Y; Wang K
    Acta Ophthalmol; 2009 Nov; 87(7):736-40. PubMed ID: 18803622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracameral bevacizumab for iris rubeosis.
    Grisanti S; Biester S; Peters S; Tatar O; Ziemssen F; Bartz-Schmidt KU;
    Am J Ophthalmol; 2006 Jul; 142(1):158-60. PubMed ID: 16815268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The treatment of the rubeosis of the iris and the neovascular glaucoma in proliferative diabetic retinopathy by means of anti-VEGF].
    Cernák M; Markovic O; Cernák A
    Cesk Slov Oftalmol; 2008 Nov; 64(6):234-6. PubMed ID: 19110964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiographic changes in iris and iridocorneal angle neovascularization after intravitreal bevacizumab injection.
    Ishibashi S; Tawara A; Sohma R; Kubota T; Toh N
    Arch Ophthalmol; 2010 Dec; 128(12):1539-45. PubMed ID: 21149776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid improvement of retinal and iris neovascularization after a single intravitreal bevacizumab injection in a patient with central retinal vein occlusion and neovascular glaucoma.
    Batioğlu F; Astam N; Ozmert E
    Int Ophthalmol; 2008 Feb; 28(1):59-61. PubMed ID: 17609852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab (Avastin) for the treatment of neovascular glaucoma.
    Chilov MN; Grigg JR; Playfair TJ
    Clin Exp Ophthalmol; 2007 Jul; 35(5):494-6. PubMed ID: 17651259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.
    Avery RL; Pearlman J; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ; Wendel R; Patel A
    Ophthalmology; 2006 Oct; 113(10):1695.e1-15. PubMed ID: 17011951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma.
    Ehlers JP; Spirn MJ; Lam A; Sivalingam A; Samuel MA; Tasman W
    Retina; 2008 May; 28(5):696-702. PubMed ID: 18463512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment.
    Avery RL
    Retina; 2006 Mar; 26(3):352-4. PubMed ID: 16508438
    [No Abstract]   [Full Text] [Related]  

  • 19. Regression of neovascular posterior capsule vessels by intravitreal bevacizumab.
    Eren E; Küçükerdönmez C; Yilmaz G; Akova YA
    J Cataract Refract Surg; 2007 Jun; 33(6):1113-5. PubMed ID: 17531712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab as adjuvant for neovascular glaucoma.
    Beutel J; Peters S; Lüke M; Aisenbrey S; Szurman P; Spitzer MS; Yoeruek E; ; Grisanti S
    Acta Ophthalmol; 2010 Feb; 88(1):103-9. PubMed ID: 18811641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.